© 2023 Merck KGaA, Darmstadt, Germany and/or its affiliates. All rights reserved. EMD Serono, Inc. is the healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada.
We have been early innovators in the field of immuno-oncology. Now, we are building on that expertise to develop current and next-generation immuno-oncology medicines that harness the patient’s immune system to fight cancer. Our active areas of research include:
- Stimulating and reprogramming tumor specific T cell response, novel therapeutics that leverage natural killer (NK) cell function, and new concepts to address resistance to checkpoint inhibition
- Leveraging myeloid cell function to either directly attack the tumor or to stimulate tumor specific T cell responses through myeloid cell biology
TARGETS UNDER INVESTIGATION
Abbreviations:
A2A/A2B, A2A and A2B receptors; PD-L1, programmed death-ligand 1; TIGIT, T-cell immunoglobulin and ITIM domain.
